Brief Title
VALVOSOFT® Pivotal Study
Official Title
Prospective, Single-arm Pivotal Study for the Treatment of Subjects With Severe Symptomatic Calcific Aortic Valve Stenosis Using Valvosoft® Non-Invasive Ultrasound Therapy (NIUT)
Brief Summary
The objective of the study is to evaluate the safety and performance of a new non-invasive ultrasound therapy (NIUT) with Valvosoft in the treatment of Calified Aortic Stenosis
Study Type
Interventional
Primary Outcome
Safety endpoint
Secondary Outcome
Rate of MACE
Condition
Aortic Valve Calcification
Intervention
VALVOSFT intervention
Study Arms / Comparison Groups
Valvosoft
Description: Treatment with VALVOSOFT device
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
60
Start Date
June 15, 2022
Completion Date
January 15, 2023
Primary Completion Date
January 15, 2023
Eligibility Criteria
Inclusion Criteria: 1. Subject suffering from severe symptomatic calcific aortic valve stenosis as defined by ESC/EACTS guidelines for the management of valvular heart disease 2021; and 2. Subject is not recommended by the local HEART Team for immediate TAVR/SAVR; or 3. Subject who refuses TAVR/SAVR, documented by local HEART Team; and 4. Age ≥18 years; and 5. Subject willing to provide a written informed consent prior to participating in the study; and 6. Subject who can comply with the study follow-up or other study requirements; and 7. Subject is eligible for the Valvosoft procedure according to Clinical Review Committee (CRC). Exclusion Criteria: 1. Subject with severe aortic regurgitation; or 2. Subject with unstable arrhythmia not controlled by medical treatment; or 3. Subjects with implanted mechanical valve in any position or bio-prosthetic valve in aortic position; or 4. Subject has a chest deformity not allowing optimal placement of Valvosoft Applicator and visualization of the aortic valve; or 5. Cardiogenic shock or other hemodynamic instability; or 6. Left Ventricular Ejection Fraction ≤30%; or 7. Subject with mean AVAI <0,24 cm²/m2; or 8. History of heart transplant; or 9. Subject requiring other cardiac surgery procedures (bypass graft surgery, mitral valve procedure, tricuspid valve procedure) within one month after Valvosoft procedure; or 10. Cardiac imaging evidence of vegetation; or 11. Acute myocardial infarction (MI) within one month prior to enrolment; or 12. Valve depth not suitable for NIUT (depth >125mm with respect to the Valvosoft imaging probe); or 13. Stroke or transient ischemic attack (TIA) ≤1 month prior to enrollment; or 14. Subject who is pregnant, or plan to become pregnant during the 12-months study follow-up period; or 15. Subject who is participating in another research study for which the primary endpoint has not been reached; or 16. Balloon aortic valvuloplasty (BAV) ≤3 months prior to enrollment; or 17. Current endocarditis; or 18. Leukopenia (WBC <4000 cell/μL), anemia (Hgb <8 g/dL), thrombocytopenia (platelet count <15.000 cell/μL), or history of coagulopathy or hypercoagulable state; or 19. Life expectancy < 6 months due to non-cardiac co-morbid conditions; or 20. Other medical, psychological, or social condition which, in the opinion of the investigator, precludes the subject from study participation; or 21. Subjects who do not have Social Security and who are under legal restraint; or 22. Subjects who cannot read or write or are mentally not or partially capable of giving informed consent.
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Christian Spaulding, MD, PhD, +32 475 84 58 36, [email protected]
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT05235568
Organization ID
CW21-02
Responsible Party
Sponsor
Study Sponsor
Cardiawave SA
Collaborators
Trium Clinical Consulting
Study Sponsor
Christian Spaulding, MD, PhD, Principal Investigator, HEGP, Paris, France
Verification Date
June 2022